Clinical trials: Degeneration
Degenerative Disc Disease, Spine Fusion
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and…
- Conditions
- Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
- Trial name
- PRECISE (NCT05037968)
- Testing
- MagnetOs Flex Matrix, Trinity Elite
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Kuros Biosurgery AG
Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
INDUCE: A Prospective 2-Year Spine Registry
The primary objective of this prospective, observational registry study is to evaluate the safety and effectiveness of Natural Matrix Protein® (NMP®) when used to promote fusion in the cervical or lumbar spine.
- Trial name
- NCT06971835
- Testing
- NMP
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Red Rock Regeneration Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
Primary Osteoarthritis, Cartilage Degeneration
DEXA Bone Density Analysis of the CoreHip® Prosthesis System
The goal of this interventional post-market follow-up study is to evaluate radiological changes in the diaphyseal bone density (Gruen Zones 3 and 4) within 24 months postoperative in patients treated with CoreHip® primary…
- Conditions
- Primary Osteoarthritis, Cartilage Degeneration, Osteoarthritis, Hip, Inflammatory Arthritis
- Trial name
- CODEX (NCT06632301)
- Testing
- Primary hip replacement with cementless stem
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Aesculap AG
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.
- Trial name
- Pre-GAIN (NCT07144137)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).
- Trial name
- Opti-GAIN (NCT07392255)
- Testing
- CTx001
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Degenerative Disc Disease, Spondylolisthesis
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion.
- Trial name
- NCT03810573
- Testing
- NB1
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Bone Biologics Corp
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor…
- Conditions
- Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
- Trial name
- CLARICO (NCT06789445)
- Testing
- OpCT-001
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- BlueRock Therapeutics
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 61 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Degenerative Disc Disease
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration.
- Trial name
- IDCT (NCT07254806)
- Testing
- IDCT (rebonuputemcel)
- Where
- 31 sites in United States
- Volunteers
- 162 people
- Sponsor
- DiscGenics, Inc.
Wilson's Disease
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease…
- Trial name
- TRADITiONAL (NCT07465718)
- Testing
- TETA 4HCl formulation, D-Penicillamine
- Where
- 10 sites in United States, China and 2 more
- Volunteers
- 38 people
- Sponsor
- Orphalan
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Intervertebral Disc Degeneration
5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures to Treat Degenerative Lumbar Spine (MASTERS-D2)
The purpose of this study is to evaluate the effectiveness of MAST techniques for anterior/lateral and posterior approaches in Degenerative Disc Disease (DDD) patients with spondylolisthesis (≥ grade I).
- Trial name
- MASTERS-D2 (NCT02617563)
- Testing
- Minimally invasive lumbar fusion
- Where
- 27 sites in Argentina, Austria and 15 more
- Volunteers
- 361 people
- Sponsor
- Medtronic Spinal and Biologics
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
- Trial name
- NCT06116890
- Testing
- KHK4951, Aflibercept Injection
- Where
- 84 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neovascular Age-related Macular Degeneration, nAMD
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular…
- Trial name
- NCT07614776
- Testing
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Where
- 81 sites in United States, Czechia and 7 more
- Volunteers
- 304 people
- Sponsor
- Amgen
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
- Trial name
- SIENNA (NCT06541704)
- Testing
- Pozelimab, Cemdisiran
- Where
- 231 sites in United States, Australia and 9 more
- Volunteers
- 975 people
- Sponsor
- Regeneron Pharmaceuticals
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07441642
- Testing
- FWY003
- Where
- 59 sites in United States, Argentina and 16 more
- Volunteers
- 272 people
- Sponsor
- Novartis Pharmaceuticals
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD)
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes.
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
- Trial name
- ReMoTe (NCT07569367)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Age-related Macular Degeneration
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
- Trial name
- NCT04151212
- Testing
- BAT5906 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Bio-Thera Solutions